OraSure Technologies, Inc. (OSUR)
| Market Cap | 389.64M |
| Revenue (ttm) | 405.47M |
| Net Income (ttm) | 53.66M |
| Shares Out | 73.80M |
| EPS (ttm) | 0.72 |
| PE Ratio | 7.33 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 628,912 |
| Open | 5.22 |
| Previous Close | 5.25 |
| Day's Range | 5.21 - 5.34 |
| 52-Week Range | 4.38 - 8.45 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 6.83 (+29.36%) |
| Earnings Date | May 8, 2024 |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection d... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is $6.83, which is an increase of 29.36% from the latest price.
News
NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board
SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced ...
OraSure Reports Q4 ‘23 Revenue of $75.9 Million
Q4 GAAP EPS of $0.27 ; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 E nters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics D...
OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th
BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certai...
OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company
The relationship expands OraSure's innovation pipeline with access to a broad portfolio of key Sapphiros products in development.
OraSure to Participate in Upcoming Investor Conferences
BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory...
OraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th
BETHLEHEM, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2023 financial results and certain...
OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year
InteliSwab® test revenue of $47.5 million in Q2 Q2 Core revenue of $37.9 million grew 4% sequentially and 3% year-over-year Q2 GAAP EPS of $(0.07); Q2 Non-GAAP EPS of $0.09 Grew cash balance to $185.9...
OraSure Technologies Elects Robert McMahon to the Board of Directors
BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory...
Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access
BETHLEHEM, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and at-home diagnostic testing, as well as non-invasive self-sampling tech...
OraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth
InteliSwab ® test revenue of $118.3 million in Q1, up 33% sequentially; Company delivers cost savings and begins to taper InteliSwab ® test production and expenses
2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET
BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain ...
OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability
InteliSwab ® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab ® revenue
2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET
BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certai...
OraSure Technologies Continues its Dedication to Ending the HIV Epidemic
Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day
OraSure Technologies to Present at Stephens Annual Investment Conference
BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytic...
OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year
InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity
OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)
FDA Clearance Received Through Partnership with Grifols to Support Screening for Risk of Alpha1- Antripsyn Deficiency (Alpha-1) in U.S. Adult Population
InteliSwab® COVID-19 Rapid Test Now Available in Amazon's Online Store
BETHLEHEM, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced ...
2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 third quarter financial results and certain...
OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test
BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced...
OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention
The effort promotes HIV testing and awareness in populations disproportionately affected by HIV The effort promotes HIV testing and awareness in populations disproportionately affected by HIV
OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health
BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced...
OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year
InteliSwab ® revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production
OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 second quarter financial results and certai...
OraSure's Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack
Race to End Hep C initiative demonstrates the ability of easy-to-administer, low-cost testing solutions to identify patients and direct them to appropriate care Race to End Hep C initiative demonstrat...